Section Arrow
HALO.NASDAQ
- Halozyme Therapeutics
Quotes are at least 15-min delayed:2026/01/01 21:41 EST
Regular Hours
Last
 67.3
-0.4 (-0.59%)
Day High 
67.94 
Prev. Close
67.7 
1-M High
72 
Volume 
977.26K 
Bid
63.5
Ask
70
Day Low
67.02 
Open
67.7 
1-M Low
61.225 
Market Cap 
7.96B 
Currency 美元 
P/E 14.28 
%Yield -- 
10-SMA 67.32 
20-SMA 65.28 
50-SMA 67.25 
52-W High 79.5 
52-W Low 47.5 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
4.74/8.38
Enterprise Value
9.47B
Balance Sheet
Book Value Per Share
4.29
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
1.02B
Operating Revenue Per Share
6.64
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.